Cannabinoids and Cancer-What’s Next? |Biomedgrid

The study of the anti-cancer activity of marijuana derivatives is currently focusing on two cannabinoids: THC and CBD. They show good in-vitro and in-vivo activity against many types of cancer cells, but their psychoactive properties (THC) and low bioavailability make them difficult to use as a cancer treatment. The development of a new technology to isolate cannabinoid acids THCA and CBDA opens new directions in the search for anticancer drugs based on their derivatives with good anti-tumor activity, better bioavailability, and a lack of psychoactive properties.